COLO B logo

Coloplast A/S Stock Price

CPSE:COLO B Community·DKK 85.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 59 Fair Values set on narratives written by author

COLO B Share Price Performance

DKK 374.70
-234.90 (-38.53%)
DKK 461.90
Fair Value
DKK 374.70
-234.90 (-38.53%)
18.9% undervalued intrinsic discount
DKK 461.90
Fair Value
Price DKK 374.70
AnalystConsensusTarget DKK 461.90
AnalystHighTarget DKK 867.71
AnalystLowTarget DKK 535.00

COLO B Community Narratives

·
Fair Value DKK 461.9 18.0% undervalued intrinsic discount

COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance

0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
·
Fair Value DKK 867.71 56.3% undervalued intrinsic discount

Global Chronic Care Tailwinds Will Drive Strong Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value DKK 535 29.2% undervalued intrinsic discount

Impact4 Efficiency Targets And Kerecis Margins Will Shape Long Term Earnings Trajectory

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DKK 867.71
56.3% undervalued intrinsic discount
Revenue
8.55% p.a.
Profit Margin
22.31%
Future PE
29.46x
Price in 2028
DKK 1.04k
DKK 535
29.2% undervalued intrinsic discount
Revenue
6.17% p.a.
Profit Margin
20.44%
Future PE
21.18x
Price in 2028
DKK 639.09

Trending Discussion

Updated Narratives

COLO B logo

COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating

Fair Value: DKK 461.9 18.0% undervalued intrinsic discount
24 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
COLO B logo

Global Chronic Care Tailwinds Will Drive Strong Long Term Upside Potential

Fair Value: DKK 867.71 56.3% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
COLO B logo

Impact4 Efficiency Targets And Kerecis Margins Will Shape Long Term Earnings Trajectory

Fair Value: DKK 535 29.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential established dividend payer.

4 Risks
3 Rewards

Coloplast A/S Key Details

DKK 28.0b

Revenue

DKK 9.1b

Cost of Revenue

DKK 18.9b

Gross Profit

DKK 16.8b

Other Expenses

DKK 2.1b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 18, 2026
9.35
67.46%
7.51%
181.5%
View Full Analysis

About COLO B

Founded
1954
Employees
17083
CEO
Gavin Wood
WebsiteView website
www.coloplast.com

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Recent COLO B News & Updates

Narrative Update Jun 16

COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating

The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.

Recent updates

No updates